Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030676 | 1.00 | TACR1 (0.48) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL4023426 | 0.92 | CASP1 (0.42) | TACR1CTSKITGB3ITGA2BALDH1A1 | |
| SCHEMBL4023417 | 0.92 | CASP1 (0.42) | TACR1CTSKITGB3ITGA2BALDH1A1 | |
| SCHEMBL4021273 | 0.90 | CTSK (0.46) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL6954029 | 0.89 | CASP1 (0.44) | CASP1 | |
| SCHEMBL6954041 | 0.89 | CASP1 (0.44) | CASP1 | |
| SCHEMBL4022449 | 0.87 | ATM (0.43) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL4022451 | 0.87 | ATM (0.43) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL4027155 | 0.81 | PTGER1 (0.42) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL4026193 | 0.80 | MEN1 (0.57) | CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171428-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-06-17 | — | — | EP | disclosed |
| US-6765005-B2 | BACTERICIDES; ENZYME INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-20 | — | — | US | disclosed |
| US-20030139377-A1 | Fab I inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-6503903-B1 | Administering 3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carboxamide derivative | SMITHKLINE BEECHAM CORPORATION | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139377-A1 | Fab I inhibitors | SERPINB1, TFPI, TFPI2 | TACR1 3626/4885CTSL 235/4885CTSB 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.